PRINCETON, N.J. -- (BUSINESS WIRE) -- Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has been nominated for the “Best Early-Stage Vaccine Biotech” Vaccine Industry Excellence (ViE) Award. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Companies are selected based on their ability to move their business from early stage to mature, the quality and diversity of their pipeline, clinical advancements, meaningful partnerships, and their success in securing funds for additional growth. The winner will be announced on April 17, 2013 at the 6th annual ViE Awards Ceremony & Gala Dinner held in conjunction with the 13th Annual World Vaccines and Expo Conference to be held April 16-18 in Washington, DC.
“We are delighted to be nominated in two consecutive years for a ViE award,” commented Thomas A. Moore, Chairman and CEO of Advaxis. “In 2012, we made tremendous progress advancing our lead program in the clinic and achieved proof-of-concept of ADXS-HPV in the indication of cervical cancer. Our mission is to continue to set the foundation to become the industry leader in immunotherapy drug development and HPV-associated cancer research. The nomination for Best Early-Stage Vaccine Biotech validates the Company’s research and clinical development over the past year.”
Officially the longest-running and largest vaccine industry event in North America, the World Vaccine Congress delivers a forum where the ever-changing dynamics of the vaccine industry are discussed and acted upon by the industry's most senior figures. For additional information please visit the World Vaccine Congress website.
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
In April 2012, Advaxis’ lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Additional information is available at the World Vaccine Congress website.
ADXS-HPV is being evaluated in 5 clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), head & neck cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study, Clinical Trial.gov Identifier NCT01671488). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, Brown University Oncology Group, and others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn
This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2012, which is available at www.sec.gov. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.